- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial | 2 | GlobeNewswire (USA) | ||
| 26.10. | CERo Therapeutics aktiviert UC Davis als klinisches Studienzentrum für CER-1236-Studie | 2 | Investing.com Deutsch | ||
| 26.10. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies | 1 | GlobeNewswire (USA) | ||
| 26.10. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers | 1 | GlobeNewswire (USA) | ||
| 26.10. | SRX Global Inc: SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies | 3 | GlobeNewswire (USA) | ||
| 07.10. | SRX Global Inc: SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies | 181 | GlobeNewswire (Europe) | SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate,... ► Artikel lesen | |
| 07.10. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 31.08. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.08. | SRX Global Inc: SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers | 491 | GlobeNewswire (Europe) | NORTH PALM BEACH, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value... ► Artikel lesen | |
| 17.07. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.07. | NSE - CERO THERAPEUTICS HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 26.06. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment | 294 | GlobeNewswire (Europe) | Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies... ► Artikel lesen | |
| 29.05. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | CERo Therapeutics: Interview With CEO Chris Ehrlich About The Immunotherapy Company | 2 | pulse2.com | ||
| 11.05. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | 752 | GlobeNewswire (Europe) | Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo... ► Artikel lesen | |
| 14.04. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial | 306 | GlobeNewswire (Europe) | Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 30.03. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | 368 | GlobeNewswire (Europe) | Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.... ► Artikel lesen | |
| 11.03. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Shareholder Update | 428 | GlobeNewswire (Europe) | Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead... ► Artikel lesen | |
| 07.01. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML | 287 | GlobeNewswire (Europe) | Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,095 | -0,62 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 10-Q, Quarterly Report | ||
| CYTOMX THERAPEUTICS | 1,816 | +3,68 % | CytomX auf Guggenheim-Gesundheitskonferenz: Hoffnungsträger Varseta-M überzeugt mit klinischen Fortschritten | ||
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics | ||
| CAPRICOR | 8,844 | +0,84 % | Capricor Therapeutics: Capricor's HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology | ||
| CORMEDIX | 4,973 | +2,30 % | CorMedix: Citizens bekräftigt "Market Outperform" nach Portfolio-Übernahme von Heron Therapeutics | ||
| MINERVA NEUROSCIENCES | 2,252 | -0,35 % | Minerva Neurosciences, Inc. - 10-Q, Quarterly Report | ||
| REPLIMUNE | 20,000 | +0,83 % | Replimune Group, Inc. - 10-Q/A, Quarterly Report | ||
| VALERIO THERAPEUTICS | 0,496 | +1,74 % | Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic | Shareholder approval and settlement and delivery of the capital increases related to the Acquisition
The Acquisition marks a major milestone in Valerio's strategy to build a leading integrated... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,574 | +0,02 % | Rani Therapeutics GAAP EPS of -$0.04, revenue of $1.7M | ||
| IO BIOTECH | 0,048 | 0,00 % | NSE - IO Biotech, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ALTO NEUROSCIENCE | 27,650 | 0,00 % | Alto Neuroscience, Inc.: Alto Neuroscience Announces Participation in Upcoming Investor Conferences | Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that... ► Artikel lesen | |
| OSR HEALTH | 0,113 | -2,75 % | OSR Health, Inc.: OSR Health Exercises $15 Million VXM01 Equity Option, Elects Settlement Through Staged Convertible Notes | Note purchase targeted to close by December 31, 2026; roadmap update on OSRK reverse takeover discussions, OTCQB uplisting and VXM01 manuscript BELLEVUE, WA / ACCESS Newswire / November 6, 2026 / OSR... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 138,86 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 333,35 | +0,11 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| KINIKSA PHARMACEUTICALS | 98,76 | 0,00 % | Milliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo Nordisk | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Behandlung von entzündlichen Herzerkrankungen entwickelt sich aktuell zu einem der lukrativsten Segmente der Pharmabranche. Das bislang... ► Artikel lesen |
CERO THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.